Paolo Bovi Selected Research

Paolo Bovi Research Topics

Disease

37	Stroke (Strokes) 11/2021 - 09/2011
29	Ischemic Stroke 04/2021 - 01/2011
17	Atrial Fibrillation 04/2021 - 01/2012
11	Hemorrhage 01/2020 - 02/2013
5	Cerebral Hemorrhage 01/2021 - 09/2011
5	Embolic Stroke 01/2019 - 01/2012
4	Brain Ischemia (Cerebral Ischemia) 01/2019 - 01/2011
3	Heart Failure 04/2021 - 01/2012
3	Embolism (Embolus) 10/2018 - 10/2011
2	Hyperlipidemias (Hyperlipidemia) 04/2021 - 01/2012
2	Hypertension (High Blood Pressure) 06/2019 - 01/2012
2	Leukoaraiosis 06/2019 - 01/2019
2	Blood Vessel Dissection 10/2017 - 12/2011
2	Patent Foramen Ovale 08/2017 - 01/2016
2	Myocardial Infarction 03/2015 - 04/2014
1	COVID-19 11/2021
1	Dementia (Dementias) 04/2021
1	Myocardial Ischemia (Ischemic Heart Diseases) 04/2021
1	Hemorrhagic Stroke 10/2018
1	Hyperthermia 03/2018
1	Hyperglycemia 03/2018
1	Infarction (Infarctions) 01/2018
1	Venous Thrombosis (Deep-Vein Thrombosis) 10/2017
1	Infections 09/2017
1	Pain (Aches) 01/2016
1	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/2015
1	Purpura 01/2015
1	Migraine with Aura (Familial Hemiplegic Migraine) 04/2014
1	Lacunar Stroke 01/2014
1	Neoplasms (Cancer) 02/2013
1	Hemorrhagic Disorders (Hemorrhagic Diathesis) 02/2013
1	Cardiac Arrhythmias (Arrythmia) 06/2012
1	Diabetes Mellitus 01/2012
1	Amaurosis Fugax 10/2011
1	Paresis (Hemiparesis) 10/2011
1	Migraine Disorders (Migraine) 01/2011
1	Parkinson Disease (Parkinson's Disease) 02/2006

Drug/Important Bio-Agent (IBA)

18	AnticoagulantsIBA 04/2021 - 02/2013
9	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2021 - 01/2012
5	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2016 - 09/2011
4	Vitamin K FDA Link 12/2020 - 11/2017
4	Metalloproteases (Metalloproteinases)IBA 01/2019 - 10/2013
4	4- Acetamido- 4'- isothiocyanatostilbene- 2,2'- disulfonic Acid (SITS)IBA 01/2018 - 01/2012
3	Dabigatran FDA Link 04/2021 - 05/2017
3	Matrix Metalloproteinases (MMPs)IBA 01/2019 - 10/2013
3	Blood Glucose (Blood Sugar)IBA 09/2018 - 01/2012
2	Biomarkers (Surrogate Marker)IBA 06/2019 - 01/2011
2	apixabanIBA 11/2017 - 09/2017
2	CholesterolIBA 01/2016 - 01/2012
2	Pharmaceutical PreparationsIBA 01/2016 - 06/2012
2	Prothrombin (Factor II)IBA 03/2015 - 01/2011
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 06/2019
1	SmokeIBA 06/2019
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2019
1	von Willebrand FactorIBA 06/2019
1	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 06/2019
1	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 01/2019
1	Particulate MatterIBA 09/2018
1	ORALIT (ORS)IBA 03/2018
1	3-O-(2'-acetoxy)benzoyl-2-glucopyranoseIBA 01/2018
1	Clopidogrel (Plavix)FDA Link 01/2018
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2018
1	RivaroxabanIBA 11/2017
1	Amyloidogenic ProteinsIBA 09/2017
1	idarucizumabIBA 05/2017
1	Warfarin (Coumadin)FDA LinkGeneric 10/2016
1	Phospholipids (Phosphatides)FDA LinkGeneric 03/2015
1	Factor V (Coagulation Factor V)IBA 03/2015
1	Dihydrotachysterol (AT 10)IBA 04/2014
1	Antiphospholipid AntibodiesIBA 04/2014
1	Antihypertensive Agents (Antihypertensives)IBA 04/2014
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 10/2013
1	Transforming Growth Factor-beta Type II ReceptorIBA 12/2011
1	Transforming Growth Factor-beta Type I ReceptorIBA 12/2011
1	Transforming Growth Factors (Transforming Growth Factor)IBA 12/2011
1	Retinaldehyde (Retinal)IBA 10/2011
1	Biological ProductsIBA 01/2011
1	factor V LeidenIBA 01/2011
1	Antipsychotic Agents (Antipsychotics)IBA 02/2006

Therapy/Procedure

12	Therapeutics 02/2020 - 06/2012
8	Secondary Prevention 02/2020 - 10/2014
5	Thrombectomy 11/2021 - 08/2017
2	Thrombolytic Therapy 01/2020 - 01/2012
1	Time-to-Treatment 01/2021
1	Aftercare (After-Treatment) 01/2019
1	Endovascular Procedures 10/2014
1	Activities of Daily Living (ADL) 01/2012